LED phototherapy could offer rosacea sufferers an effective, long-term treatment to manage and control symptoms. LED pioneers Dermalux’s new Tri-Wave MD device - with its three clinically validated wavelengths - has been used successfully to provide non-invasive, pain-free in-clinic treatments for inflammatory skin conditions, such as acne and psoriasis – reducing inflammation and promoting skin healing[1], [2], [3]. Now it is being used by medical professionals as an equally effective option for managing the challenging symptoms associated with rosacea.
Around one in 20 people in the UK suffer from rosacea. It is a chronic skin condition mainly affecting the face, causing flushing, visible blood vessels and acne-like spots[i]. Some people also suffer itching or burning sensations of the affected areas, as well as skin-thickening. While, rosacea’s causes are not perfectly understood, one of the reasons could be the result of dysfunctional hair follicles and their associated sebaceous glands (pilosebaceous units)[ii]. Genetics, an overactive immune system, demodex skin mites and environmental factors, such as over-exposure to the sun, are also believed to play a role.
Traditional treatments depend on the severity of the flare-up. Patients are encouraged to avoid lifestyle triggers including sun exposure, or make changes to their diet, make-up and skincare. Mild to moderate flare-ups are typically managed using a combination of skincare products, such as retinoids, topical medicines, and more severe cases may call for oral antibiotics.
Let there be light
The new Dermalux Tri-Wave MD is acknowledged to be the most powerful LED phototherapy device on the market, delivering the optimal dose of light energy. The device is flexible, as it uses multiple wavelengths concurrently from a singular wavelength LEDs to ensure clinicians can target multiple symptoms in a single treatment, while reducing treatment time. And uniquely Tri-Wave MD maintains sufficient energy when using one or three wavelengths at the same time. This ensures constancy of treatment, optimal dosing and superior results.
The device uses three clinically proven wavelengths: Blue 414nm, Red 633nm, and Near Infrared 830nm. These are harnessed in four key ways in the treatment of rosacea:
- Modulation of inflammatory pathways: Both Red and NIR light have been shown to downregulate pro-inflammatory cytokines (such as IL-6 and TNF-alpha), helping to reduce chronic inflammation that underpins rosacea flare-ups.
- Enhanced cellular repair and regeneration: Both Red and NIR wavelengths promote mitochondrial activity, particularly via cytochrome c oxidase, increasing ATP production and supporting tissue repair and barrier function. This is critical for rosacea-prone skin, which often presents with a compromised epidermal barrier.
- Non-thermal, non-invasive mechanism: Unlike many energy-based devices, Dermalux delivers therapeutic light without causing trauma making it safe for vascular sensitivity and reactive skin — both common features in rosacea patients.
- Vascular support and microcirculation: LED Phototherapy has been shown to improve microcirculation and lymphatic drainage, which may contribute to the reduction of diffuse erythema and facial flushing in some patients.
“I haven’t seen a treatment as effective for inflamed skin and rosacea”
Clinicians are using the Dermalux Tri-Wave MD as a treatment modality to successfully calm the inflammation, reduce redness and improve overall skin resilience in rosacea sufferers. Dr Ian Strawford, founder of Skin Excellence Clinics says: “The Dermalux Tri-Wave MD’s USP is its power. Used alone or alongside other treatments, it calms the skin and stimulates regenerative pathways. I have seen an increase in patient satisfaction, as downtime post-multi-disciplinary treatments has halved. The wound healing capacity is unparalleled. I haven’t seen a treatment as effective for inflamed skin and rosacea”.
Dr Strawford recently conducted an in-clinic study on four female patients with rosacea and other inflammatory conditions. Each was treated with the Dermalux Tri-Wave MD weekly for 20 minutes, over the course of six weeks.
“All four patients experienced improvements in their overall skin quality, decreased inflammation and diminished pigmentation,” explains Dr Strawford. “No patients reported any adverse reactions, such as photosensitivity. Each were satisfied with the outcomes, self-reporting enhanced self-confidence and overall mood,” he reported.
Dr Strawford also underlines the role the Tri-Wave MD can play in perpetuating patient engagement: “I encourage my patients to build Dermalux treatment into an ongoing maintenance plan and it is a great, cost-effective, standalone treatment, with exceptional results. From a business perspective, my wider team can deliver the treatment, freeing up my time.”
Learn more
A good place to learn more in the first instance is the recently launched Dermalux Academy, which is more than just an educational platform; it’s a community where professionals can collaborate and thrive. The platform’s extensive resources ensure that practitioners are well-informed and up-to-date with the latest developments in the field of LED Phototherapy. Joining professionals can also connect with peers and experts, exchange insights, and share successful cases, fostering a community-driven approach to learning.
For more information, visit: dermaluxled.com/education/
[1] Ablon G. J Clin Aesthet Dermatol. 2018;11:21–7.
[2]Edge D, et al. J Clin Aesthet Dermatol. 2019;12:E61–8.
[3] Sorbellini E, et al. J Med Case Rep. 2020;14:22.
